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Abstract
Background—Disease-modifying anti-rheumatic drugs (DMARDs) are recommended for
virtually all patients with rheumatoid arthritis (RA). We investigated the use of DMARDs in
patients with RA in a nationally representative sample of visits to US physicians in the National
Ambulatory Care Medical Survey (NAMCS).
Methods—We analyzed NAMCS visit data from 1996 through 2007 if the physician noted a
diagnosis of RA. DMARD utilization was based on the medications listed by the physician. We
used generalized linear models to examine the adjusted associations between DMARD use and
potential predictors.
Results—Among 859 visits with a diagnosis code of RA were identified over the study period,
404 (47%, 95% confidence interval (CI) 44-50%) had an associated DMARD. The percentage of
RA visits with DMARDs increased slightly over the twelve years (p = 0.048), with biologic
DMARDs increasing to 20% of visits after their introduction (p for trend < 0.001). In fully
adjusted models, Black race was associated with a 30% reduction in DMARD prescribing (risk
ratio, RR, 0.70, 95% CI 0.48 – 1.00). A visit to a rheumatologist was the strongest correlate of
DMARD prescribing (RR 2.33, 95% CI 1.89 – 2.86). Among visits to non-rheumatologists,
Blacks were significantly less likely than Whites to receive a DMARD (RR 0.39, 95% CI
0.17-0.92), but not among visits with rheumatologists (RR 0.81, 95% CI 0.52-1.27).
Conclusions—In the NAMCS survey, most visits coded with RA did not have an associated
DMARD prescription. Blacks were less likely to receive DMARDs than Whites, particularly when
visiting non-rheumatologists.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory arthritis associated with
pain, disability, and increased mortality. Disease modifying anti-rheumatic drugs
(DMARDs) represent the standard of care for RA, with demonstrated ability to reduce pain
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and disability.1 Whereas the traditional model of RA treatment had been a “pyramid”
approach, beginning with nonsteroidal anti-inflammatory drugs (NSAIDs) and
glucocorticoids for the first phase of treatment, the recommended strategy now includes
immediate DMARD therapy.1 These agents are recommended by the major rheumatologic
societies and in rheumatic disease specialty practices, over 90% of patients with RA
received DMARDs.1-3 This approach has been widely embraced; in fact, US national care
quality organizations have included DMARD treatment for RA as a performance standard.4
Since the 1990s, DMARD options have proliferated with increased numbers of both
synthetic small molecules and biologic treatments, e.g., TNF inhibitors, B-cell depleting
therapy, a co-stimulatory agonist, and an IL-6 antagonist.5 Despite the increased number of
DMARD options and the agreement on their importance in RA, several studies suggest that
many patients do not receive these therapies. A study using Medicare data from two US
states from 1996-2004 showed that 30% of beneficiaries with RA filled a DMARD
prescription during the 12 months after cohort entry.6 Data from British Columbia during
1996-2000 found only 43% of RA patients received DMARD treatment during 60 months of
follow-up.7 Furthermore, a very recent study using data from Medicare Managed Care plans
found that 59% of beneficiaries with RA used a DMARD in 2005 and 67% in 2008.8 These
studies suggest that there may be widespread underuse of DMARDs for RA, but the reasons
remain unclear. Prior studies identified older age, depression and lack of a rheumatology
visit as correlates of not using a DMARD,6-8 suggesting potential disparities in DMARD
use. However, these studies covered a short duration and focused on a relatively narrow
range of patients, mostly older Medicare beneficiaries.
To overcome these limitations, we examined DMARD use for RA using nationally
representative data on office visits with physicians from the National Ambulatory Medical
Care Survey.9 Based on previous studies from other therapeutic areas suggesting the receipt
of specific interventions often differs by race,10-13 we examined the effect of race, ethnicity
and physician specialty on DMARD prescribing. The effects of race and ethnicity were first
analyzed in the whole cohort. To examine whether access to rheumatology care modified a
possible race and ethnicity effect, we also analyzed this relationship in samples stratified on
whether the visit was with a rheumatologist.
METHODS
Study Sample
We studied data from NAMCS, an annual visit-based cross-sectional survey conducted in
physicians’ offices. NAMCS includes a nationally representative probability sample of
ambulatory physician practices across the US using a multi-stage cluster strategy, selecting
physicians by geographic location and provider specialty. Physicians and their office staff
are trained to complete the survey for all visits in a randomly sampled week. The purposeful
sampling strategy and use of weights allows one to generalize to the approximately 650
million office visits made annually to physicians in the US. Physicians and patients are not
sampled repetitively across years. Our study sample consisted of all visits recorded in
NAMCS 1996-2007 with a diagnosis of RA listed among any of the diagnoses on the visit
survey form.
The study protocol was approved by the Institutional Review Board of the Partners
Healthcare System.
Rheumatoid Arthritis Treatment
Up to eight new or ongoing medications and up to three diagnoses were recorded for each
visit in NAMCS. The primary outcome for these analyses was DMARD prescribing as
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recorded on the visit survey form. We included both non-biologic DMARDs (azathioprine,
cyclosporine, D-penicillamine, gold preparations, hydroxychloroquine, leflunomide,
methotrexate, and sulfasalazine) and biologic DMARDs (abatacept, adalimumab, anakinra,
etanercept, infliximab, and rituximab). A variable on the survey indicates whether the
prescription is new or a continuation. Prescriptions for oral glucocorticoids, opioids, and
NSAIDs (non-selective and selective) were also assessed.
Potential Correlates of DMRD Prescribing
The NAMCS visit survey includes a limited set of variables possibly related to DMARD
prescribing. These include: sociodemographic variables concerning the presenting patient,
such as age, gender, race (White, Black, and Other), ethnicity (Hispanic, non-Hispanic, and
Unknown), health insurance coverage, and region of residence; the number of non-DMARD
drugs prescribed; and the type of provider who conducted the visit. We categorized the types
of providers as rheumatologists or non-rheumatologists.
Statistical Analyses
We assessed the percentage of RA visits associated with a DMARD prescription for each of
the 12 study years. The variables were compared across visits with and without DMARDs
and then risk ratios were estimated using Generalized Linear Models, accounting for the
clustered nature of the visits and sampling weights. The unit of analysis is the visit coded for
RA and not persons with RA; RA cases are not followed longitudinally over 12 years, since
different RA individuals are sampled every year. The variables associated with DMARD use
were examined in a series of models with an increasing number of covariates, testing
whether the effect of race and/or ethnicity was diminished with increasing adjustment.
Region of residence and health insurance status were not significant predictors in univariate
or multivariate models and were removed from analyses. We added the rheumatologist
covariate as the last variable to determine whether the effect of race and ethnicity were
mediated by access to rheumatology care. Based on initial results, we further examined
whether the effect of race and ethnicity were modified by rheumatology care by comparing
risk ratios (RRs) in two sets of adjusted models – one for visits to rheumatologists and one
for visits to non-rheumatologists. We also assessed the interaction effect of race and
ethnicity by rheumatology care.
We used SUDAAN statistical software version 10.0.1 (Research Triangle Institute, Research
Triangle Park, NC) to account for the complex survey design.
RESULTS
We identified 859 visits with a diagnosis of RA over the 12 year study period. When
weighted to the US population, this total represents approximately 3.7 million visits over
this period that included a diagnosis of RA. Characteristics of these 859 visits are described
in Table 1. The majority of patients were 45 years and over and 76% were female. Most
patients were White and non-Hispanic. None were pregnant or had HIV, two potential
contraindications to the use of certain DMARDs.
Of the 859 visits associated with RA, 378 (44%) were associated with 3 or more non-
DMARD drugs, 315 (37%) with 1 or 2, and 166 (19%) with none. About half of the visits
were to a rheumatologist, with DMARD users much more likely to see a rheumatologist
than non-users.
Of these 859 visits, 404 (47%, 95% confidence interval 44-50%) were associated with a
prescription for a DMARD, representing approximately 1.9 million visits in the US. The
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remaining 455 visits without an associated DMARD represent 1.8 million visits in the US.
The percentage of visits with a DMARD prescription increased slightly over the study
period (Figure 1). The percentage with a biologic DMARD gradually increased since they
were introduced in 1999. In 2007, there were approximately 293,000 visits in the US
associated with a DMARD and 110,000 were with a biologic DMARD. Of the 455 visits
without an associated DMARD, 16 (3.5%) had eight medications listed on their NAMCS
form (the maximum permitted) and 83 (1.2%) used oral glucocorticoids.
We examined the correlates of any DMARD and biologic DMARD use in a series of
multivariable models (Table 2). In Model 1 that includes the calendar year of the visit, race,
and ethnicity, Black race was associated with a trend toward a reduced risk ratio of any
DMARD use (RR 0.69, 95% CI 0.42 – 1.12). In Models 2 and 3, the effect of Black race
was maintained and was statistically significant with increasing adjustment. The effect of
race on the use of biologic DMARDs was qualitatively similar to any DMARD use, but it
was not statistically significant (see Table 2). Furthermore, Black race was not significantly
associated with a lower risk of any DMARD use (RR 0.81, 95% CI 0.52-1.27) in a fully
adjusted model restricted to the 377 visits made to rheumatologists. When the same adjusted
model was run for the 482 visits to nonrheumatologists, Black race had a stronger
association with any DMARD non-use (RR 0.39, 95% CI 0.17-0.92) than among visits to
rheumatologists (Table 3), however the p-value for interaction was 0.15.
Trends in the use of other drugs commonly used to manage pain and inflammation were also
examined in the same 859 NAMCS visits (see Figure 2). During the 12 years of NAMCS
studied, we found that 4-11% of the visits listed an opioid with an approximate doubling of
use in recent years. Oral glucocorticoids and NSAIDs/coxibs were each used by one-quarter
to one-third of subjects with RA without any clear time trends.
DISCUSSION
The early and aggressive use of disease modifying anti-rheumatic drugs (DMARDs) has
improved the care and outcomes of RA.14, 15 However, several studies suggest that the
potential benefits of DMARDs are not being reaped by many people suffering with RA
because of under-use of these agents.6-8 To guide strategies to improve DMARD use, a
better understanding of this problem and its determinants is required. We examined a US
national survey over a 12-year time period, investigating whether race and/or ethnicity
disparities exist in DMARD utilization.
Over the study period, we found that fewer than half of RA visits listed a DMARD, and the
DMARD treatment rates improved only slightly over the 12 year study period. This was
surprising as a substantial increase has been noted in several other studies.6, 8 It is unclear
whether the relatively small increase that we observed in comparison to other studies was
due to differences in the population or related to how DMARD use was measured. Black
race was a significant correlate of DMARD non-use, with Blacks having a 30% reduced
utilization of any DMARD compared to Whites; similar trends were observed for biologic
DMARDs. Black race was noted to be a correlate of DMARD non-use in another US study
among Medicare beneficiaries.6 As well, Black race has been found to be correlated with
less frequent use of many health services, including total joint replacement, cardiac re-
vascularization, and organ transplant.11, 13, 16, 17 Potential reasons for such treatment
disparities include differences in access to care, attitudes and preferences of providers and
patients, and differences in clinical presentation across different patient groups.18
It is noteworthy that in the entire sample of visits, the effect of Black race was attenuated
when the rheumatologist indicator was added to the model. This suggests that lack of access
Solomon et al. Page 4













to a rheumatologist may be one mediator of the racial disparity. There was also evidence
that the effect of Black race was modified by whether or not the visit was to a
rheumatologist (Table 3). Health insurance status was not significantly associated with use
of DMARDs.
While seeing a rheumatologist was strongly associated with DMARD use for all racial and
ethnic groups, most persons with RA are not seen by rheumatologists, in the US or
abroad.6, 7, 19, 20 Our data demonstrate that DMARD use has not increased over a period
when (a) at least five new DMARDs were introduced, (b) scientific data clarified the
important role of DMARDs,15 and (c) DMARDs for RA became a quality measure for
health plans in the US. The lack of prescribing improvement speaks to the slow pace with
which medical practice catches up to clinical evidence -- 17 years as estimated by the
Institute of Medicine.21
This study has important limitations, mostly associated with NAMCS. The NAMCS survey
does not allow one to confirm diagnoses. Thus, it is impossible to know the accuracy of the
RA code. Based on the calculated national estimates compared with other data sources, it is
likely that some visits coded with RA are inaccurate.22 Typically, this type of
misclassification biases toward the null, making it more difficult to observe the effect of
other variables, such as Black race. Moreover, the medication lists are not validated against
prescription data, but prior work suggests that NAMCS data are acceptably accurate.23 The
scope of NAMCS is a great strength of this study. The purposeful sampling strategy used by
NAMCS – including urban and rural areas and patients of diverse racial and ethnic
backgrounds -- allows one to generalize to the entire US. As well, we studied a relatively
large group of visits sampled over a long period. Prior studies are typically restricted to
specific patient groups or narrow geographic regions, while NAMCS represents a national
sample. However, NAMCS does not include information about several sociodemographic
variables of interest, including household income and education level. Health insurance
status was not associated with DMARD use in these data, but future studies should also
determine whether Black race is a surrogate for socioeconomic issues and/or limited access.
While these variables may underlie some of the differences in DMARD treatment that we
observed, the models presented herein point towards race as being an important patient
characteristic that may serve as a useful target for further epidemiologic studies and
interventions.
In conclusion, we studied 12 years of data from a nationally representative sample of
ambulatory visits in the US. Among visits identified with a diagnosis of RA, only 47% had a
DMARD associated with them. DMARDs were prescribed much less often for Blacks than
for Whites, especially among visits to non-rheumatologists. This finding suggests that part
of the reason that Black race may be associated with reduced DMARD use is that Blacks
have more limited access to rheumatologists. Interventions should be considered to improve
DMARD prescribing, focusing particularly on patients who do not see rheumatologists and
on Black patients who appear to have less access to rheumatologists. Health insurance status
was not significantly associated with DMARD use in these data, but future studies should
also determine whether Black race is a surrogate for socioeconomic issues and/or limited
access. Expanding access to DMARDs will likely require improving collaborative care
between generalists and specialists as well as learning more about patients’ preferences and
how they weight the potential benefits and risks of these agents.
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- In a large US national survey of office visits to physicians, 47% of visits with a
diagnosis of RA were associated with a DMARD.
- In fully adjusted models, Black race was associated with a 30% reduction in DMARD
prescribing and a visit to a rheumatologist was the strongest correlate of DMARD
prescribing, more than doubling the likelihood of receiving a DMARD.
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The figure shows the percent of NAMCS visits with rheumatoid arthritis noted where a
DMARD was listed. Data are graphed in three-year blocks across the 12 year study period,
and are shown separately for any DMARD (black circles), non-biologic DMARDs (grey
circles), and biologic DMARDs (white circles). There is only a black circle at the first time
period (1996-1998) because all DMARDs were non-biologic. Over the period studied, there
was a slight increase in any DMARD use (p for trend = 0.048), while there was an increase
in biologic DMARD use (p for trend < 0.001).
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The figure shows the percent of NAMCS visits with rheumatoid arthritis noted where a non-
DMARD medication (oral glucocorticoid, opioid, or NSAID) was listed. Data are graphed
across the 12 year study period in three-year blocks, and are shown separately for oral
glucocorticoids (black circle), opioids (grey circle) and NSAIDs/coxibs (white circle).
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Table 1
Characteristics of the patients seen for the visits associated with rheumatoid arthritis in NAMCS from
1996-2007, by DMARD use status
DMARD use No DMARD use DMARD use No DMARD use
N sample (%) N weighted to all ambulatory US visits (%)
N 404 455 1,880,000 1,789,000
Age, years
    0-44 57 (14%) 69 (15%) 258,553 (14%) 259,392 (15%)
    45-64 216 (53%) 186 (41%) 1,011,000 (54%) 745,247 (42%)
    65 and over 131 (25%) 200 (44%) 610,784 (32%) 784.084 (44%)
Gender
    Female 305 (75%) 348 (76%) 1,429,000 (76%) 1,414,000 (79%)
    Male 99 (25%) 107 (24%) 451,641 (24%) 375,124 (21%)
Race
    White 374 (93%) 405 (89%) 1,736,000 (92%) 1,570,000 (88%)
    Black 21 (5%) 36 (8%) 103,480 (6%) 171,865 (10%)
    Other 9 (2%) 14 (3%) 40,617 (2%) 47,207 (3%)
Ethnicity
    Hispanic 39 (10%) 29 (6%) 211,996 (11%) 148,308 (8%)
    Non-hispanic 351 (87%) 402 (88%) 1,617,000 (86%) 1,528,000 (85%)
    Unknown 14 (3%) 24 (5%) 51,097 (3%) 112,678 (6%)
Non-DMARD drugs
    0 38 (9%) 128 (28%) 182,568 (10%) 456,997 (26%)
    1-2 146 (36%) 169 (37%) 712,700 (38%) 665,730 (37%)
    3 or more 220 (54%) 158 (35%) 985,074 (52%) 665,997 (37%)
Rheumatology visit
    Yes 273 (68%) 104 (23%) 1,333,000 (71%) 477.041 (27%)
    No 131 (32%) 351 (77%) 547,806 (29%) 1,312,000 (73%)
DMARD, disease modifying anti-rheumatic drug. See text for a list of these medications. Some column percentages may not equal 100% because
of rounding.
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Table 3
Multivariable correlates of disease modifying anti-rheumatic drugs use in NAMCS among visits to
rheumatologists and non-rheumatologists, 1996-2007
Rheumatology visits (n = 377) Non-Rheumatology visits (n = 482)
Any DMARD use, risk ratio (95% confidence interval)
Age, years
    0-44 1.05 (0.84-1.31) 1.27 (0.78-2.08)
    45-64 1.08 (0.95-1.22) 1.25 (0.89-1.78)
    65+ 1.00 1.00
Race/ethnicity
    Black, non-Hispanic 0.81 (0.52-1.27) 0.39 (0.17-0.92)
    Hispanic 1.18 (1.02-1.37) 1.05 (0.73-1.52)
    Other 1.20 (0.92-1.56) 1.25 (0.68-2.30)
    White 1.00 1.00
Gender
    Female 0.96 (0.78-1.17) 0.92 (0.65 – 1.30)
    Male 1.00 1.00
Medication number*
    3 or more 1.43 (1.08-1.91) 4.12 (2.01 – 8.41)
    1-2 1.40 (1.03-1.92) 2.09 (1.07 – 4.06)
    none 1.00 1.00
Notes: All variables were adjusted for in each model.
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